Modified neurotoxin comprising neurotoxin including structural modification,
wherein the structural modification alters the biological persistence, preferably
the biological half-life, of the modified neurotoxin relative to an identical neurotoxin
without the structural modification. The structural modification includes addition
or deletion of a leucine-based motif or parts thereof. In one embodiment, methods
of making the modified neurotoxin include using recombinant techniques. In another
embodiment, methods of using the modified neurotoxin to treat biological disorders
include treating autonomic disorders, neuromuscular disorders or pains.
